Century Therapeutics Stock
Century Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Brent Pfeiffenberger
- Employees
- 78
- Market cap
- $248 M
- IPO
- 18/06/2021
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy.…
Century Therapeutics stock: price history
1D
-8.7%
1W
-6.8%
1M
-26.3%
6M
-47.3%
YTD
+37.7%
1Y
+146.0%
2Y
-12.7%
5Y
-92.9%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~0% stronger price swings than usual
Ask the agents about Century Therapeutics
Analyst assessment of Century Therapeutics
PRICE TARGET LOW
US$2.00
CONSENSUS
US$7.50
MEDIAN
US$4.50
PRICE TARGET HIGH
US$19.00
0
STRONG BUY
7
BUY
2
HOLD
0
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 21/04/2026
Century Therapeutics stock metrics
P/E
-1.32
P/B
1.21
EV/EBITDA
-2.52
RETURN ON EQUITY
-14.9%
NET MARGIN
0.0%
DEBT/EQUITY
0.15
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
55.9%
FLOAT SHARES
101,253,698
AVG. DAILY VOLUME (30D)
695,180
Insider transactions (SEC)
Carr Douglas
Pfeiffenberger Brent
Russotti Gregory
Pfeiffenberger Brent
Carr Douglas
Institutional holders
Comparable stocks
Frequently asked questions about Century Therapeutics stock
What does Century Therapeutics do?
Century Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Brent Pfeiffenberger, the company employs around 78 people.
The IPO was on 18/06/2021; the stock trades on NASDAQ under the ticker IPSC.
What do analysts say about Century Therapeutics stock?
9 analysts rate the stock, the consensus is Buy (as of 21/04/2026).
The average price target is US$7.50, ranging from US$2.00 to US$19.00, with a median of US$4.50.
This is an external assessment, not a statement by Market Jury.
When does Century Therapeutics report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 0% stronger than usual.
Does Century Therapeutics pay a dividend?
No, Century Therapeutics currently does not pay a dividend.
Which stocks are comparable to Century Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Century Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Century Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.